# US 10,865,244 B2 · Nucleic acids encoding agonistic antibodies that bind CD40

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,865,244 B2
- Document ID: US10865244B2
- Status: Granted
- Kind: B2
- Application number: 15/490,589
- Filed: 2017-04-18
- Published: 2018-03-08
- Granted: 2020-12-15
- Earliest claimed: 2016-04-18
- Assignees: Celldex Therapeutics, Inc.
- Applicants: Celldex Therapeutics, Inc.
- Inventors: Tibor Keler; Joel Goldstein; Laura A. Vitale; Lizhen He; Tom O'Neill; Andrea Crocker; Karuna Sundarapandiyan; Lawrence J. Thomas; Jenifer Widger
- Web page: https://patentgrep.com/patent/US10865244B2

## CPC

- C07K 16/2803: {against the immunoglobulin superfamily}
- A61K 39/385: Haptens or antigens, bound to carriers
- A61K 39/39541: {against normal tissues, cells}
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/04: Immunostimulants
- C07K 14/54: Interleukins [IL]
- C07K 14/715: for cytokines; for lymphokines; for interferons
- C07K 16/2878: {against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95}
- A61K 2039/505: {comprising antibodies}
- C07K 14/70575: {NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154 (NGF C07K14/48, TNF C07K14/525)}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/74: Inducing cell proliferation
- C07K 2317/75: Agonist effect on antigen
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Isolated monoclonal agonistic antibodies which bind to human CD40 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.

## Claims

### Claim 1

An isolated nucleic acid encoding the variable region of a light chain, heavy chain, or both light and heavy chains of an antibody which binds to human CD40, wherein the heavy and/or light chain variable regions comprise the amino acid sequence set forth in SEQ ID NOs: 17 and 18, respectively.

### Claim 2 (depends on 1)

An expression vector comprising the nucleic acid of claim 1.

### Claim 3 (depends on 2)

A cell transformed with an expression vector of claim 2.

### Claim 4

An isolated nucleic acid encoding the variable region of a light chain, heavy chain, or both light and heavy chains of an antibody which binds to human CD40, wherein the heavy and/or light chain variable regions comprise the CDR sequences from the heavy and/or light chain variable regions comprising the amino acid sequences set forth in SEQ ID NOs: 17 and 18, respectively.

### Claim 5 (depends on 4)

An expression vector comprising the nucleic acid of claim 4.

### Claim 6 (depends on 5)

A cell transformed with an expression vector of claim 5.

### Claim 7

An isolated nucleic acid encoding the variable region of a light chain, heavy chain, or both light and heavy chains of an antibody which binds to human CD40, wherein the heavy chain variable region comprises the CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOs: 19, 21, and 23, respectively, and the light chain variable region comprises the CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOs: 25, 27, and 29, respectively.

### Claim 8 (depends on 7)

An expression vector comprising the nucleic acid of claim 7.

### Claim 9 (depends on 8)

A cell transformed with an expression vector of claim 8.

### Claim 10 (depends on 3)

A method of producing an antibody comprising culturing the cell of claim 3, wherein the antibody is produced.

### Claim 11 (depends on 6)

A method of producing an antibody comprising culturing the cell of claim 6, wherein the antibody is produced.